CBD Life Sciences Inc. (CBDL)

CBD Life Sciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Mar 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	0.18	0.17	0.16	0.08	0.23	0.08
Revenue Growth (YoY)	29.13%	4.31%	92.17%	-63.09%	183.66%	-84.92%
Cost of Revenue	0.1	0.09	0.07	0.06	0.11	0.04
Gross Profit	0.08	0.08	0.09	0.03	0.12	0.04
Selling, General & Admin	0.13	0.1	0.89	6.15	0.5	0.45
Other Operating Expenses	0	0	0	0.02	-	-
Operating Expenses	0.19	0.16	0.95	6.17	0.5	0.45
Operating Income	-0.11	-0.08	-0.86	-6.14	-0.38	-0.41
Interest Expense	-	-	-	-	-0.07	-
Other Non Operating Income (Expenses)	-	-	-	-	-	-0.26
EBT Excluding Unusual Items	-0.11	-0.08	-0.86	-6.14	-0.45	-0.67
Impairment of Goodwill	-	-	-	-	-1.24	-
Other Unusual Items	-	-	-	-	-	-0.19
Pretax Income	-0.11	-0.08	-0.86	-6.14	-1.69	-0.86
Net Income	-0.11	-0.08	-0.86	-6.14	-1.69	-0.86
Net Income to Common	-0.11	-0.08	-0.86	-6.14	-1.69	-0.86
Shares Outstanding (Basic)	136	136	136	78	3	1
Shares Outstanding (Diluted)	136	136	136	78	3	1
Shares Change (YoY)	8.24%	-	73.92%	2403.73%	125.06%	-
EPS (Basic)	-0.00	-0.00	-0.01	-0.08	-0.54	-0.62
EPS (Diluted)	-0.00	-0.00	-0.01	-0.08	-0.54	-0.62
Free Cash Flow	-0.02	-0.02	-0.87	-6.44	-0.66	-0.77
Free Cash Flow Per Share	-	-	-0.01	-0.08	-0.21	-0.56
Gross Margin	45.06%	47.70%	53.48%	32.90%	53.24%	46.00%
Operating Margin	-60.21%	-47.01%	-536.57%	-7364.79%	-170.03%	-517.78%
Profit Margin	-60.21%	-47.01%	-536.57%	-7364.79%	-750.08%	-1081.21%
Free Cash Flow Margin	-10.98%	-9.96%	-544.92%	-7728.80%	-292.48%	-965.75%
EBITDA	-0.05	-0.02	-0.81	-	-	-0.34
EBITDA Margin	-29.07%	-13.77%	-	-	-	-
D&A For EBITDA	0.06	0.06	0.05	-	-	0.08
EBIT	-0.11	-0.08	-0.86	-6.14	-0.38	-0.41
EBIT Margin	-60.21%	-47.01%	-	-	-170.03%	-

Updated Jun 5, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.